CIED Infection: Incidence, Treatment, Expenditures limited to, outpatient parenteral antimicrobial administration, visits with healthcare providers, and reimplantation of a new device at a subsequent visit.
The purpose of this study was to estimate the incidence, treatment intensity, and annual healthcare expenditures for patients receiving CIED therapy who experience a CIEDrelated infection during the first year after their device implantation. Management interventions for CIED infection were classified into 4 distinct treatment intensity categories, from least intensive, where device-related infection was managed on an outpatient basis only with no device removal, to most intensive, in which there is a diagnosis of severe sepsis, managed with at least 1 inpatient admission, and device removal. Expenditures were estimated for 4 categories in comparison with patients with no infection, and they were calculated separately for patients with an initial implant and for those with replacement implants.
Methods Data
Data for this analysis came from the Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases from Truven Health Analytics Inc from 2009 to 2012. The databases include records from >170 million unique patients since 1995. Claims include physician office visits, hospital stays, and pharmacies. Data from individual patients are integrated from all providers of care, maintaining all healthcare utilization and cost record connections at the patient level. This database is nationally representative and includes data from 150 employers and 21 health plans, representing 130 unique carriers. 12 A protocol describing the study was submitted to the New England Institutional Review Board (NEIRB) and deemed exempt from review (NEIRB no. .
Study Population
Patients were selected for study inclusion if they had a record of an initial CIED implant or a replacement (full implant or generator only) during the calendar years 2009 to 2012. CIED patients were classified into 1 of 2 mutually exclusive groups: (1) initial implant or (2) replacement implant based on the algorithm outlined in Figure 1 and Table I in the Data Supplement. Patients also had to have 6 months continuous medical and prescription enrollment before their CIED implant index visit (implant procedure codes are provided in Table II in the Data Supplement). Patients were excluded if they had a record of a major cardiac procedure in addition to CIED implantation during their index visit or if the implant type was unknown ( Figure 2 ). Excluded cardiac procedures and International Classification of Diseases Ninth Revision procedure codes are provided in Table III in the Data Supplement. 11
Defining Infections
CIED infection was defined by either of 2 conditions occurring ≤365 days after initial or replacement implant: (1) a patient had the presence of infection International Classification of Diseases Ninth Revision-CM code 996.61 (infection and inflammatory reaction because of cardiac device, implant, and graft) and (2) a patient had a record of at least one of the following infection diagnoses: 996.61, other postoperative infection 998.59, septicemia 038, 038.x, 038.xx, or bacteremia 790.7 with a device-related procedure code for the removal or revision of their implant during the same visit.
WHAT IS KNOWN
• Cardiac implantable electric device (CIED) infections are estimated to occur at a rate of 1% to 2%.
• The rate of CIED infections is increasing out of proportion to the rate of CIED implantations.
• CIED infections are associated with high morbidity and mortality, which translates into high costs for the healthcare system.
WHAT THE STUDY ADDS
• There is substantial cost associated with management of patients with CIED infections across the spectrum of infection severity, ranging from superficial surgical site infections to severe sepsis.
• The cost of care to a commercial insurer categorized by treatment intensity for CIED infection is defined.
• These data can be used to assess and compare the potential economic impact of interventions designed to reduce CIED infections. For patients undergoing initial implant, either CIED infection scenario could occur during the same hospital stay as their index implant. However, for the replacement cohort, it was not possible to discern if they were undergoing a replacement procedure to manage a CIED infection or if their infection occurred after the replacement. If an infection code was present on the index visit, it was assumed that the replacement was the result of an infection that initiated before the replacement visit. Hence for the replacement cohort, infections were only counted if they occurred 1 day after the inpatient or outpatient index visit during which the replacement procedure was performed.
Within the MarketScan database, an outpatient visit was identified as a visit with claims for services that were rendered in a doctor's office, hospital outpatient facility, emergency room, or other outpatient facility. An inpatient visit was identified as a visit with claims for services that included a room and board charge in a hospital, that is, had at least 1 overnight stay.
All patients with a CIED infection based on aforementioned criteria were further categorized by the treatment intensity associated with managing their device infection. Four mutually exclusive groups were analyzed: infection treatment intensity category 1: infection not managed by inpatient admission nor implant removal or revision, infection treatment intensity category 2: infection managed by inpatient admission but no implant removal or revision, infection treatment intensity category 3: infection managed by an implant removal or revision (Table IV in the Data Supplement) for removal and revision coding) either in an inpatient or outpatient setting, and infection treatment intensity category 4: infection and concomitant severe sepsis (septic shock and multiple organ dysfunction syndrome) and managed in an inpatient setting with implant removal or revision.
Variables of Interest
The primary outcomes of interest for this analysis were the presence of CIED infection, CIED infection management by treatment intensity (categories 1-4) and healthcare expenditures. Independent variables of interest included insurance plan, year of index procedure, baseline comorbidities, and patient demographics including, age, sex, and insurance type.
Two comorbidity scores were utilized: the Charlson Comorbidity Index (CCI) score 13 and the Elixhauser Comorbidity Index (ECI) score. 14 Each score is a composite of comorbidities recorded at the index visit or ≤6 months before (See Tables V and VI in the Data Supplement for complete code listings.).
In addition to the CCI and the ECI, data on specific comorbidities and drug therapies that are known risk factors for CIED infection were recorded. 6, [15] [16] [17] Each of these were analyzed independently 6 months before initial or replacement index procedure date. These comorbidities included: advanced chronic kidney disease (ie, stage 4 or 5) or end-stage renal disease or receiving hemodialysis, heart failure, diabetes mellitus, and hypertension. Drug therapies that were evaluated included: immunomodulator therapy, corticosteroid therapy, oral anticoagulant therapy, or antiplatelet agent therapy (See Table  VII Table II in the Data Supplement. CIED Infection: Incidence, Treatment, Expenditures
Statistical Analysis
The characteristics, comorbid conditions, and expenditures were summarized separately for initial and replacement patients by those having a CIED infection versus those who did not. As an alternative to typical significance testing, baseline characteristics and comorbid conditions for patients with and without CIEDs were compared using standardized mean differences (SMDs) because of the large differences in sample sizes. The SMD (difference in means divided by the SD) is an index that is used to quantify the size of the difference, the effect size, between the 2 groups. Unlike measures of statistical significance (ie, P values), the SMD is independent of sample size. Although there is no standard threshold to determine the significant difference between the 2 groups when using SMD, an absolute value of 0.2 is a qualitative measure of a small effect size, and an absolute value of SMD>0.5 is a moderate effect size. 18 Kaplan-Meier models were utilized to generate survival curves, and product limit estimates for annualized rate-of-infection and time-to-infection ≤365 days post index for both cohorts.
Annual expenditures were estimated for patients who experienced a CIED infection versus those without CIED infection among patients with 12 months continuous enrollment. Annual expenditures were estimated for all CIED patients with infection (overall) and by treatment intensity category. Annual expenditures were estimated with generalized linear models, utilizing a γ distribution and a log link function. All multivariable expenditure models were run separately on patients with initial implants and patients with replacement implants. All models were controlled for type of implant (permanent pacemakers [PPMs], ICD, and cardiac resynchronization therapy), as well as patient demographics and comorbid conditions. All analyses were performed using SAS version 9.2 (SAS, Cary, NC).
Results
There were 199 459 patients enrolled in the MarketScan Research Databases for the years 2009 to 2012 who had a record of a full cardiac implant or generator replacement. Patients who had a major cardiac procedure in addition to implant on their index visit were then excluded leaving 194 430 patients. Application of all inclusion and exclusion criteria resulted in a final sample size of 93 031 patients: 62 414 (67%) were identified as having initial implants and 30 617 (33%) were identified as replacements ( Figure 2 ).
The annualized risk of infection within the first year after implant, as estimated using Kaplan-Meier models, was 1.18% for initially implanted patients and 2.37% for patients having replacements ( Figure 3 ). Median time-to-infection within 1 year post implant was 35 days for patients with initial implants and 23 days for patients with replacement implants.
Patients who experienced a CIED infection were slightly younger (initial: 67.4 and replacement: 68.0) than those who did not (initial: 70.0, SMD 0.1769 and replacement: 71.4, SMD 0.2138 Table 1 ). The majority of patients in each cohort had Medicare insurance coverage. Regional distribution was similar whether patients experienced a CIED infection or not and whether patients had an initial or replacement implant.
About implant type (PPM, ICD, or cardiac resynchronization therapy), PPM dominated all cohorts with 52 610 PPM implants out of 93 031 total implants. Percentage of patients with a PPM implant type ranged from 44.0% of replacement implant patients with infection to 58.3% of initial implant patients who did not experience infection ( Table 1 ). The large group of PPM patients was likely because of higher rate of Medicare patients and average age in all cohorts. There were differences in implant setting for CIED infection rates across cohorts. Patients who experienced CIED infections had their index procedure in an inpatient setting more frequently than patients without infection.
The comorbid conditions of interest include advanced chronic kidney disease (ie, stage 4 or 5 or end-stage renal disease with or without hemodialysis), heart failure, diabetes mellitus, and hypertension ( Table 2 ). All comorbidities and Figure 3 . Estimated annualized rate of infection among initial and replacement implant cohorts. Kaplan-Meier models were utilized to generate survival curves and product limit estimates for annualized rate of infection for the period ≤365 d post index for each cohort. CIED Infection: Incidence, Treatment, Expenditures drug therapies are shown by cohort (initial and replacement) and by those patients experiencing a CIED infection versus those who did not. Across both cohorts, patients experiencing a CIED infection had a higher average ECI (initial 4.1 and replacement 4.0) and CCI scores (initial 5.6 and replacement 5.4) than those not experiencing an infection (ECI initial 3.5 and replacement 3.4) and (CCI initial 5.2 and replacement 5.2). For patients in the replacement implant cohort, 36% of patients who experienced CIED infection had evidence of a previous CIED infection in the 6 months before their CIED index implant, compared with 2% of the patients who did not experience infection. The majority of the patients with earlier evidence of infection in the CIED infection group had an infection of treatment intensity category 1 (data not shown). This suggests that if the infections identified for these patients represented inadequately treated previous infections, that were not resolved before the index visit, they did not generally progress to a higher level of treatment post index date.
The distribution of patients across the infection treatment intensity categories for each cohort (initial and replacement) was found. Treatment intensity category 1, which is an infection not managed by inpatient admission nor implant removal, represented 38.4% of the initial and 47.2% of the replacement cohorts that experienced infection. Treatment intensity category 2, infection managed by inpatient admission but no implant removal, represented 19.4% of the initial implant cohort and 15.8% of the replacement cohort that experienced infection. Treatment intensity category 3, an infection managed by an implant removal either in an inpatient or outpatient setting, represented 38.8% of the initial implant cohort and 33.7% of the replacement cohort that experienced infection. Treatment intensity category 4, an infection with severe sepsis and managed in an inpatient setting with implant removal, had the lowest rates and represented 3.4% of the initial implant cohort and 3.2% of the replacement cohort that experienced infection. CRT-D indicates cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemakers; ICD, implantable cardioverter-defibrillator; PPM, permanent pacemaker; and SMD, standardized mean difference.
*Note that absolute value of SMD>0.2 is a small effect size; absolute value of SMD>0.5 is a moderate effect size. CIED Infection: Incidence, Treatment, Expenditures
Multivariable expenditure models were used to estimate the incremental expenditure of all treatment intensities combined compared with no infection (Figure 4 ) and to estimate the expenditure for each treatment intensity category ( Figure 5A and 5B 
Discussion
In today's fiscally strained healthcare environment, there is a critical need for better data to estimate the true healthcare costs associated with CIED infection. Not only are these infections complex and potentially life threatening but also rates of device infection are increasing faster than the rate of CIED utilization. 6 Earlier estimates of cost associated with treating CIED infections have been limited to expenditures incurred during index admission. 11 The current investigation, performed on a large scale, administrative claims database including both inpatient and outpatient records, is the largest study to date to estimate CIED infection treatment costs taking into account healthcare expenditure associated with infection management after hospital discharge. Moreover, it is the first study to classify patients according to the treatment intensity categories and explore the impact of infection management interventions, and the cost of care across the treatment intensity spectrum. We identified 93 031 patients with CIED implantations, 1306 (initial and replacement) of whom had a record of infection within the year after their index implant. The estimated overall annualized infection rate was 1.18% for the initial implant cohort and 2.37% for the replacement implant cohort. Incremental expenditures for patients with device infection, when compared with those without infection, were $47 885 in the initial cohort and $45 512 in the replacement cohort. Definitions of CIED infection, sources of data, and resulting CIED infection rates differ in the published literature making comparisons between studies complicated. However, the overall rates of CIED infection observed in our analysis are within the overall range reported in the published literature. For example, in a study of ICD Registry data from 2006 to 2009, matched to Medicare fee-for-service claims data, 17 there was an overall rate of device infection of 1.7% (3390/200 900), whereas the generator replacement cohort had a higher rate of infection compared with initial implant cohort (1.9% versus 1.6%, P<0.001). Our study is consistent with these data in that the higher infection rate is observed in the replacement cohort. The overall rates (both initial and replacement) estimated by Prutkin et al 17 (1.9% replacement and 1.6% initial) are slightly different than those reported here (2.37% replacement and 1.18% initial). This could be attributed to the interplay of many factors, including different patient population (Medicare versus privately insured), care setting (inpatient only versus inpatient and outpatient), different years of the study (2006-2009 versus 2009-2012) , different definitions of infection, and different inclusion/exclusion criteria (reimplant for infection was excluded versus reimplant for infection was not excluded; no exclusion for major cardiac procedure at index versus exclusion for major cardiac procedure at index). Similarly, Polyzos et al 19 reported an average infection rate of 1.2% (0.3% min to 4.5% max) for the 30 retrospective cohort studies included in their systematic literature review and meta-analysis of risk factors for CIED infection. Consistent with the range of infection rates reported, the identified studies varied in implanted device types, data sources (administrative and clinical databases), definition of device infection (for example, requiring device extraction versus inclusion of likely superficial or incisional infections), and inclusion/exclusion criteria. Aside from variations in reported infection rates in different studies, it should be noted that overall infection rates have not decreased in the past 2 decades, despite improvement in device manufacturing and more experience in implantation, suggesting a need for better preventive strategies.
Although multiple investigations have sought to estimate the infection rate after CIED implantations, the literature focusing on the cost implications of CIED infection is modest. 15 The current investigation adds to the literature by carefully defining and separately analyzing infection rates for initial and replacement implant population and by quantifying expenditures by novel treatment intensity categories. These treatment intensity categories reflect clinical pathways through the lens of the administrative coding data elements available in a payer database. As such, they are limited, as are all administrative payerdatabase analyses, in their ability to mirror clinical practice because the database does not contain detailed clinical information such as that found in clinical notes. However, these categories still reflect clinical treatment pathways to the extent possible with the data elements available in an administrative database and are the first reported attempt to relate expenditures to established clinical guidance. In addition, it is important to use real-world data as a recent Consensus Statement on ICDs 20 explains that clinical trials studying these devices are limited to homogenous population, making it difficult to extrapolate when they could be used in the general population.
The current investigation focused on healthcare expenditures linked to device infection treatment intensity as determined by 4 distinct categories, the first 2 involving treatment without implant removal and the last 2 including implant removal. This distinction between removal and nonremoval is important as current practice guidelines by American Heart Association for the diagnosis, prevention, and management of CIED infection recommend device removal for CIED generator or lead infection (class I indication). 21 Treatment intensity category 1 is likely to include patients that are clinically diagnosed as having a superficial or incisional infection at the pocket site. Practice guidelines suggest that these patients can be managed with antimicrobial therapy alone, without hardware removal or revision; and these can be managed appropriately in the outpatient setting. It is conceivable that treatment intensity category 1 may also include some patients with a true CIED pocket infection whose treatment falls outside of practice guidelines that call for removal of all hardware. Unfortunately, the available coding does not have the granularity required to distinguish between these 2 clinical scenarios. The relationship of patients in treatment intensity category 2 to a specific clinically defined population represented by the current practice guidelines is more complex. This category may include the following: patients with a CIED pocket infection who are too sick for device removal, patients with CIED pocket infection whose treatment falls outside of practice guidelines, patients with a superficial infection who require inpatient treatment because of comorbid or other conditions, and possibly patients who fit other clinical scenarios.
Given the limitations of the payer-based database for the patient population studied, our results indicate that a majority of CIED-related infections, as defined by data elements in an administrative database, fall into the 2 treatment intensity categories (categories 1 and 2) that do not include implant removal. Although category 1 and 2 infections are not treated with device removal, the estimated annual incremental expenditures in comparison with patients without infection are still Figure 5 . A, Estimated incremental expenditures by treatment intensity category for the initial implant cohort. Incremental expenditures at 12 mo are shown for each treatment intensity group. The difference represents the cost of infection in each group when compared with patients without an infection. Treatment intensity categories 1 to 4 were each tested for difference from the no infection cohort. Each were statistically significantly different at the P=0.001 level. B, Estimated incremental expenditures by treatment intensity category for replacement implant cohort. Incremental expenditures at 12 mo are shown for each treatment intensity group. The difference represents the cost of infection in each group when compared with patients without an infection. Treatment intensity categories 1 to 4 were each tested for difference from the no infection cohort. Each were statistically significantly different at the P=0.001 level.
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substantial. For initial and replacement cohort patients in treatment intensity category 1, this corresponds to estimated annual incremental expenditures of $16 651 and $26 857, respectively, in comparison with patients without infection and $104 077 and $43 541, respectively, for initial and replacement cohort patients in treatment intensity category 2 in comparison with patients without infection.
Treatment intensity categories 3 and 4 correspond to CIED-related infections that were treated with device removal. The estimated annual incremental expenditures in comparison with patients without infection are $45 291 and $48 759, respectively, for initial and replacement cohort patients in treatment intensity category 3 and $279 744 and $362 696, respectively, for initial and replacement cohort patients in treatment intensity category 4. Although the percentage of patients with infection who are in treatment intensity category 4 is small, the estimated annual incremental expenditures for this group in both initial and replacement cohorts were large, consistent with the complexity of infection and associated care.
For the replacement cohort, the estimated annual incremental expenditures for treatment intensity category 3 are similar to those found for treatment intensity category 2. This is not the case for patients in the initial cohort. The patients in treatment intensity category 2 in the initial cohort have an estimated annual incremental expenditure of $104 077, whereas patients in treatment intensity category 3 have an estimated annual incremental expenditure of $45 291. This higher cost of care for initial implant patients with CIED infection who are managed as inpatients but with implant retention (treatment intensity category 2) may be because of these patients being deemed too high risk for device explantation, leading to prolonged hospitalization, longer duration of antimicrobial therapy, and higher complication rates compared with those patients where the implant can be removed (category 3) for source control and cure of infection. The median number of inpatient days for the 12 months postimplant was longer for both the initial and replacement cohorts in treatment intensity category 2 (initial 12 days and replacement 11 days) compared with treatment intensity category 3 (initial 6 days and replacement 5 days). It should be noted that interpretation of these results is complicated by the definitions of the treatment intensity categories: treatment intensity category 2 requires at least 1 inpatient visit with a diagnosis of infection, whereas there is no requirement for an inpatient visit for inclusion in treatment intensity category 3. Given this caveat, these data are still generally consistent with the assertion that patients in treatment intensity category 2 are too high risk clinically for device explantation. However, it does not explain why this only translates into greater incremental expenditures for category 2 in the initial implant cohort. Unfortunately, the administrative databases do not provide insight into the clinical decision-making process to further analyze this result in general, or the appropriateness of care for an individual patient.
Although the overall rate of infection is low, the fact that >4 million pacemakers and ICD implants are currently in use in the United States 6 suggests that these incremental differences in expenditure could be substantial. Besides financial cost, CIED infections are also associated with significant morbidity and mortality. Therefore, strategies to minimize the CIED infection risk should be a priority for future research. Considering that the majority of early-onset infections are related to generator pocket infections, 22, 23 the strategies may include the use of chlorhexidine for local antisepsis at the time of implantation, screening and eradicating Staphylococcus aureus colonization, and the use of commercially available antibacterial envelope impregnated with minocycline and rifampin (that elute antibiotics locally in the generator pocket >7-10 days) and has been shown to reduce rate of CIED infection in multiple studies. [24] [25] [26] [27] [28] 
Limitations
The primary limitation of our analysis is its reliance on International Classification of Diseases Ninth Revision coding from an administrative claims-based database. Inclusion of International Classification of Diseases Ninth Revision coding alone has been shown to have low specificity in identifying true CIED infection cases. 29 Administrative claims do not include data on patients' symptoms, clinical course, or decision-making process. Therefore, we are limited in our ability to infer care differences between hospitalizations among patients by treatment intensity associated with infection. Also, we could not assess the appropriateness of device retention or removal in different infection treatment intensity categories. The use of device registries that include clinical data may shed more light on the decision-making process behind these management interventions. Finally, the current analysis is limited to device infections that occur within the first year of an implant procedure. This may have implications on the type of infections, which were analyzed. CIED-lead infections may occur any time after device implantation because there can be hematogenous seeding of device leads from distance sources of bloodstream infection years after the implant. Therefore, CIED-lead infections may be underrepresented in our analysis. 30 
Conclusions
CIED infections are associated with significant incremental cost of care across all infection treatment intensity categories. Device infections that present with concomitant sepsis, requiring inpatient admission and implant removal, are associated with highest cost. Optimal management of CIED infections can be clinically challenging with an added burden on the patient, healthcare provider and payer. Strategies to minimize the rate of CIED infection should be a priority for healthcare providers, implanting these devices and for future research in CIED infections.
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